Literature DB >> 20624244

Analgesic effect of subanesthetic intravenous ketamine in refractory neuropathic pain: a case report.

Osama Elsewaisy1, Barry Slon, John Monagle.   

Abstract

A 59-year-old male patient with progressive neuropathic pain secondary to chronic idiopathic axonal polyneuropathy responded poorly to conventional therapies including gabapentin, tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors and opioids. Following continuous intravenous administration of low dose ketamine, an N-methyl-D-aspartic acid receptor antagonist, 20 mg/h for 5 days, almost complete pain relief was obtained without significant side effects. The analgesic effect lasted 10-12 weeks and the ketamine infusion was repeated, with this pattern being maintained for 3.5 years. This supports the growing body of evidence that ketamine may be useful in the management of refractory chronic neuropathic pain. We discuss chronic idiopathic axonal polyneuropathy, neuropathic pain mechanisms, and the use of ketamine in this report.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20624244     DOI: 10.1111/j.1526-4637.2010.00863.x

Source DB:  PubMed          Journal:  Pain Med        ISSN: 1526-2375            Impact factor:   3.750


  3 in total

Review 1.  [Recommendations of the updated LONTS guidelines. Long-term opioid therapy for chronic noncancer pain].

Authors:  W Häuser; F Bock; P Engeser; G Hege-Scheuing; M Hüppe; G Lindena; C Maier; H Norda; L Radbruch; R Sabatowski; M Schäfer; M Schiltenwolf; M Schuler; H Sorgatz; T Tölle; A Willweber-Strumpf; F Petzke
Journal:  Schmerz       Date:  2015-02       Impact factor: 1.107

2.  Ketamine, as adjuvant analgesics for patients with refractory cancer pain, does affect IL-2/IFN-γ expression of T cells in vitro?: A prospective, randomized, double-blind study.

Authors:  Naibao Zhou; Zhijian Fu; Hao Li; Kaiguo Wang
Journal:  Medicine (Baltimore)       Date:  2017-04       Impact factor: 1.889

3.  Case Report of Subanesthetic Intravenous Ketamine Infusion for the Treatment of Neuropathic Pain and Depression with Suicidal Features in a Pediatric Patient.

Authors:  Garret Weber; JuHan Yao; Shemeica Binns; Shinae Namkoong
Journal:  Case Rep Anesthesiol       Date:  2018-07-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.